IPSEN (OTCMKTS:IPSEY – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $45.40 and traded as high as $46.6650. IPSEN shares last traded at $46.45, with a volume of 289 shares traded.
Analysts Set New Price Targets
IPSEY has been the topic of a number of recent analyst reports. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold”.
Get Our Latest Research Report on IPSEN
IPSEN Price Performance
The stock has a 50-day simple moving average of $43.42 and a 200-day simple moving average of $45.40.
About IPSEN
IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.
Featured Stories
- Five stocks we like better than IPSEN
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
